Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.
Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.
复制标题
评估化疗药物的心脏毒性：超声心动图的作用。
DOI：
10.1007/s12410-012-9163-3
复制
发表时间：
2012
影响因子：
0.9
通讯作者：
Scherrer-Crosbie,Marielle
中科院分区：
文献类型：
--
作者：
Tan,TimothyC;Scherrer-Crosbie,Marielle
癌症治疗的进步使患者有足够的生存时间来经历治疗相关的心脏并发症。特别是，化疗引起的心功能障碍显著影响癌症患者的发病率和死亡率。化疗是否存在心脏毒性，传统上是通过临床症状和左心室射血分数（LVEF）的降低来评估的。然而，在这一适应症中，LVEF作为亚临床心脏毒性指标缺乏准确性，其预后价值也存在争议。重点是早期识别亚临床和左心室功能障碍，以便癌症患者和他们的医生做出明智的治疗选择。超声心动图是一种方便、无创的测量心功能的工具，在心脏毒性的诊断中起着重要作用。这篇综述的重点是超声心动图在检测心脏毒性中的作用，并将讨论传统的和最近的超声心动图评估亚临床心脏毒性的方法。
Advancements in cancer treatment have resulted in sufficient survival length for patients to experience treatment-related cardiac complications. In particular, chemotherapy-induced cardiac dysfunction significantly impacts morbidity and mortality rates in cancer patients. The presence of cardiotoxicity from chemotherapy has been traditionally assessed using clinical symptoms and decreases in left ventricular ejection fraction (LVEF). However, in this indication, LVEF lacks accuracy as a measure of subclinical cardiotoxicity and its prognostic value is controversial. There is an emphasis to identify subclinical and left ventricular dysfunction early, in order to allow cancer patients and their physicians to make informed decisions about therapeutic options. Echocardiography is a readily available non-invasive tool to measure cardiac function and plays a major role in the diagnosis of cardiotoxicity. This review focuses on the role of echocardiography in detecting cardiotoxicity, and will discuss conventional and more recent echocardiographic approaches for assessing subclinical cardiotoxicity.